Abstract: The present invention relates to a method for preparing a fermented ginseng concentrate. The method first involves subjecting ginseng to an extraction with a solvent to obtain a ginseng extract. Next, pectinase and beta-galactosidase are added to the ginseng extract under conditions effective to ferment the ginseng extract. The fermented extract is then concentrated to produce a fermented ginseng concentrate. The method may further involve drying the fermented ginseng concentrate to obtain fermented ginseng powder.
Type:
Grant
Filed:
May 14, 2009
Date of Patent:
September 24, 2013
Assignee:
Il Hwa Co., Ltd.
Inventors:
Dae Keun Sim, Jong Hwan Sung, Seung Kwon Lee, Min Goo Cho
Abstract: The present invention relates to a method for preparing a fermented ginseng concentrate. The method first involves subjecting ginseng to an extraction with a solvent to obtain a ginseng extract. Next, pectinase and beta-galactosidase are added to the ginseng extract under conditions effective to ferment the ginseng extract. The fermented extract is then concentrated to produce a fermented ginseng concentrate. The method may further involve drying the fermented ginseng concentrate to obtain fermented ginseng powder. Combinations of the invention ginseng materials with other active and/or inactive materials are also disclosed.
Type:
Application
Filed:
August 17, 2010
Publication date:
February 23, 2012
Applicant:
IL HWA CO., LTD.
Inventors:
David C. KONN, Dae Keun Sim, Jong Hwan Sung, Seung Kwon Lee, Min Goo Cho
Abstract: The present invention relates to a method for preparing a fermented ginseng concentrate. The method first involves subjecting ginseng to an extraction with a solvent to obtain a ginseng extract. Next, pectinase and beta-galactosidase are added to the ginseng extract under conditions effective to ferment the ginseng extract. The fermented extract is then concentrated to produce a fermented ginseng concentrate. The method may further involve drying the fermented ginseng concentrate to obtain fermented ginseng powder.
Type:
Application
Filed:
May 14, 2009
Publication date:
November 18, 2010
Applicant:
IL HWA CO., LTD.
Inventors:
Dae Keun SIM, Jong Hwan SUNG, Seung Kwon LEE, Min Goo CHO
Abstract: The present invention relates to carbapenem derivatives of Formula I, wherein X is carbonyl or sulfonyl, and a preparation method thereof. The carbapenem derivatives of the invention have excellent antibacterial properties and are thus useful as antibiotics.
Type:
Grant
Filed:
May 18, 2000
Date of Patent:
August 20, 2002
Assignees:
Korea Institute of Science and Technology, Il Hwa Co., Ltd.
Inventors:
Sang Woo Park, Dong Kin Kim, Kye-Jung Shin, Yong Koo Kang, Yong Zu Kim, Yong Ho Chung, Hong Woo Lee, Jae Doo Huh, Sang Joo Lee, Il Hong Suh, Bong Suk Ko
Abstract: According to this invention, Prevotella sp. S-1 strain (Bacteroidaceae family, KFCC-10923) is cultured in a medium supplemented with Panax ginseng saponin so as to collect the metabolites of saponin generated and accumulated in the medium, thus ensuring their selective production with high efficiency.This invention related to a process for the preparation of the metabolites of protopanaxadiol saponin, wherein Prevotella sp. S-1 strain (Bacteroidaceae family, KFCC-10923), is cultured at a medium supplemented with Panax ginseng saponin and then, the metabolites of protopanaxadiol saponin contained in the medium--20-O-.beta.-D-glucopyranosyl-20(s)-protopanaxadiol, 20-O-?.alpha.-L-arabinopyranosyl-20(s)-protopanaxadiol, and 20-0-?.alpha.-L-arabinopuranosyl(1.fwdarw.6)-.beta.-D-glucopyranosyl!-20(s )-protopanaxadiol --are generated and accumulated for collecting them thereof.
Abstract: This invention relates to ginsenoside Mc with formula (I), ##STR1## an intestinal flora metabolite of ginseng saponin and anticancer agent containing it as an active ingredient. In addition to a novel compound, the anticancer agent of this invention consists of one active ingredient elected from compound K, compound Y or 20(S)-protopanaxatriol, intestinal flora metabolites of ginseng saponin, together with one or more pharmaceutically acceptable carriers. Said agent is a novel type of potential anticancer agent since it has immunopotentiating actions including inhibitory actions on the vascularization of tumors and extravasation of cancer cells.